Context Therapeutics, Inc. CNTX
NASDAQ · United States · Health Technology
$0.3097-0.00 (-1.49%)
Market closed· · USD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market closed· · USD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Total return, dividends included.
CT-202 is a Nectin-4 x CD3 T cell engaging bispecific antibody Phase 1 trial is evaluating CT-202 as a monotherapy treatment in patients with urothelial, colorectal, and triple-negative breast cancers PHILADELPHIA, Sept. 09, 2026 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging (“TCE”) bispecific antibodies for solid tumors, today announced that the first patient has been dosed in the P
The biotech will now focus on the two other BiTEs in its pipeline, CTIM-76 and CT-202.
Where the price sits against its 50- and 200-day moving averages.
Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.
Opportunities center on frontline immunotherapy combinations, biomarker and companion diagnostics, AI-enabled pathology, minimally invasive screening, precision therapies for uterine sarcomas, and tele-oncology expansion in underserved regionsDublin, Aug. 07, 2026 (GLOBE NEWSWIRE) -- The "Endometrial Cancer - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)" has been added to ResearchAndMarkets.com's offering. Global Endometrial Cancer Market Forecast to Reach US
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.